Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications.

•This is the first study to assess the safety of cell-derived vaccine in at-risk children.•The cell culture-derived (TIVc) and egg-derived (TIV) trivalent influenza vaccines were generally well tolerated in children at risk of influenza.•The TIVc and TIV had similar safety profiles in children at risk of influenza.•There were no cases of severe fever or serious adverse events (AEs) with either TIVc or TIV.•The most common solicited AEs were pain, irritability, and headache.